Cutler Group’s Viridian Therapeutics VRDN Stock Holding History

Cutler Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,550	Closed	-$20.8K	–	5751
2022 Q1	$28K	Buy	+1,550	New	+$29.8K	﹤0.01%	2772

Other funds holding VRDN

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's VRDN Position: Q2 2022 in Review

Cutler Group sold out of Viridian Therapeutics (VRDN) in Q2 2022, closing a stake of 1,550 shares — an estimated $20.8K sold.

Cutler Group first reported a position in VRDN in Q1 2022 and held it in 1 quarter. The position peaked at $28K in Q1 2022. 84 funds tracked by Wall St. Rank hold VRDN as of Q2 2022.

Cutler Group reported no remaining Viridian Therapeutics position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 1,550 Viridian Therapeutics shares in Q2 2022, an estimated $20.8K.
Cutler Group first reported a position in Viridian Therapeutics in Q1 2022 and held it in 1 quarter.
Cutler Group's Viridian Therapeutics position peaked at $28K in Q1 2022.
84 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.